{
    "clinical_study": {
        "@rank": "147860", 
        "arm_group": [
            {
                "arm_group_label": "NEXThaler 100/6 mcg DPI", 
                "arm_group_type": "Experimental", 
                "description": "Single dose (4 inhalations)of NEXThaler 100/6 mcg DPI: total dose 400/24 mcg"
            }, 
            {
                "arm_group_label": "NEXThaler 200/6 mcg DPI", 
                "arm_group_type": "Experimental", 
                "description": "Single dose (4 inhalations)of NEXThaler 200/6 mcg DPI: total dose: 800/24 mcg"
            }, 
            {
                "arm_group_label": "NEXThaler placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single dose (4 inhalations)"
            }, 
            {
                "arm_group_label": "NEXThaler 100/6 mcg plus CB", 
                "arm_group_type": "Experimental", 
                "description": "Single dose (4 inhalations) NEXThaler 100/6 mcg administered with activated charcoal (Charcoal Block): total dose 400/24 mcg"
            }, 
            {
                "arm_group_label": "NEXThaler 200/6 mcg plus CB", 
                "arm_group_type": "Experimental", 
                "description": "Single dose (4 inhalations) NEXThaler 200/6 mcg administered with activated charcoal (Charcoal Block): total dose 800/24 mcg"
            }, 
            {
                "arm_group_label": "Flixotide Accuhaler 500 mcg", 
                "arm_group_type": "Active Comparator", 
                "description": "Single dose (2 inhalations) of fluticasone propionate"
            }
        ], 
        "brief_summary": {
            "textblock": "The study is aimed to assess the dose proportional total systemic exposure (when the\n      administration is without the activated charcoal) to B17MP (active metabolite of BDP) and\n      its lung bioavailability (when the administration is with the activated charcoal) after\n      single inhalation of CHF 1535 NEXThaler DPI at two dose strengths.\n\n      At the same time, the study will assess if the lung deposition and the total systemic\n      exposure to Formoterol is affected by increasing doses of BDP."
        }, 
        "brief_title": "Lung Bioavailability and Total Systemic Exposure to Beclomethasone17MonoPropionate and Formoterol Across Two Strengths of NEXThaler Inhalation Powder", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Asthmatic", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of asthma as defined by Global Initiative for Asthma (GINA) 2011\n\n          -  Asthmatic patients already treated with low daily doses of Inhaled Corticosteroids\n             (ICS) (eg budesonide or equivalent lower than 400 mcg/day) or low dose of ICS/Long\n             Acting Beta2 Agonists (LABA) fixed combinations.\n\n          -  Patients with Forced Expiratory Volume in 1 sec (FEV1) >= 70 % of predicted values\n\n          -  Non or ex-smokers\n\n          -  Body Mass Index (BMI) >= 18.5 and <= 32 kg/m2\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating women unless using acceptable methods of contraception\n\n          -  Diagnosis of Chronic Obstructive Pulmonary Disease (COPD)\n\n          -  History of near fatal asthma\n\n          -  Patients with abnormal QTcF at screening Visit\n\n          -  Hospitalization due to asthma exacerbation within 4 weeks prior to the screening\n             visit or during the run-in period.\n\n          -  Lower respiratory tract infection within 4 weeks prior to the screening visit or\n             during the run-in period.\n\n          -  History of drug addiction or excessive use of alcohol ;\n\n          -  Diagnosis of restrictive lung disease.\n\n          -  Patients treated with oral or parenteral corticosteroids in the previous 2 months\n             before the screening visit (3 months for parenteral depot corticosteroids)\n\n          -  Significant medical history or any laboratory abnormality indicative of a significant\n             underlying condition"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01738087", 
            "org_study_id": "CCD-1205-PR-0087", 
            "secondary_id": "2012-002370-30"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "NEXThaler 100/6 mcg DPI", 
                    "NEXThaler 100/6 mcg plus CB"
                ], 
                "intervention_name": "NEXThaler 100/6 mcg DPI", 
                "intervention_type": "Drug", 
                "other_name": "Fixed combination of BDP plus formoterol fumarate"
            }, 
            {
                "arm_group_label": "Flixotide Accuhaler 500 mcg", 
                "description": "Active comparator", 
                "intervention_name": "Flixotide Accuhaler 500 mcg", 
                "intervention_type": "Drug", 
                "other_name": "Fluticasone Propionate"
            }, 
            {
                "arm_group_label": [
                    "NEXThaler 200/6 mcg DPI", 
                    "NEXThaler 200/6 mcg plus CB"
                ], 
                "intervention_name": "NEXThaler 200/6 mcg DPI", 
                "intervention_type": "Drug", 
                "other_name": "Fixed combination of BDP plus formoterol fumarate"
            }, 
            {
                "arm_group_label": "NEXThaler placebo", 
                "description": "Placebo comparator", 
                "intervention_name": "NEXThaler placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Charcoal", 
                "Fluticasone", 
                "Beclomethasone", 
                "Formoterol"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "patients", 
            "Adult"
        ], 
        "lastchanged_date": "January 29, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Manchester", 
                    "country": "United Kingdom", 
                    "zip": "M23 9QZ"
                }, 
                "name": "The Medicine Evaluation Unit"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "6", 
        "official_title": "A Phase II, Monocentric, Open, Randomized, 6-way Cross-over Clinical Pharmacology Study to Evaluate the Lung Bioavailability of BDP/B17MP and Formoterol and the Total Systemic Exposure Across Two Different Strengths of CHF 1535 NEXThaler Dry Powder Inhaler (Fixed Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate 100/6 Mcg and 200 Mcg) Administered With and Without Activated Charcoal in Adult Asthmatic Patients.", 
        "other_outcome": [
            {
                "description": "the following parameters will be evaluated: AUC0-4h, AUC0-12h, Cmax and tmax", 
                "measure": "Plasma glucose", 
                "safety_issue": "Yes", 
                "time_frame": "from predose until 12 hours postdose"
            }, 
            {
                "description": "the following parameters will be evaluated: HR AUC0-12/12h", 
                "measure": "Heart rate (HR)", 
                "safety_issue": "Yes", 
                "time_frame": "from predose until 12 hours postdose"
            }, 
            {
                "description": "the following parameters will be evaluated: AUC0-24, Cmin and tmin", 
                "measure": "Plasma cortisol", 
                "safety_issue": "Yes", 
                "time_frame": "from predose until 24 hours postdose"
            }, 
            {
                "description": "the following parameters will be evaluated: AUC0-4h, AUC0-12h, Cmin ad tmin", 
                "measure": "Plasma potassium", 
                "safety_issue": "Yes", 
                "time_frame": "from predose until 12 hours postdose"
            }, 
            {
                "description": "the following parameters will be evaluated: SBP AUC0-12/12h and DBP AUC0-12/12h", 
                "measure": "Systolic and Diastolic Blood Pressure (SBP and DBP)", 
                "safety_issue": "Yes", 
                "time_frame": "from predose until 12 hours postdose"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Formoterol AUC0-t and B17MP AUC0-t", 
            "safety_issue": "No", 
            "time_frame": "from predose until 12 hr post dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01738087"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The following parameters will be evaluated: AUC0-t, AUC0-12h, AUC0-inf, Cmax, tmax, t1/2", 
                "measure": "BDP pharmacokinetic (PK) parameters", 
                "safety_issue": "No", 
                "time_frame": "from predose until 12 hr post dose"
            }, 
            {
                "description": "the following pharmacokinetic parameters will be evaluated: AUC0-12, AUCinf, Cmax, tmax, t1/2", 
                "measure": "Other PK parameter of B17MP and formoterol", 
                "safety_issue": "No", 
                "time_frame": "from predose until 12 hours postdose"
            }
        ], 
        "source": "Chiesi Farmaceutici S.p.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chiesi Farmaceutici S.p.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}